Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Yifeng Bao"'
Autor:
Zhaoduan Liang, Wenfang Chen, Yunzhuo Guo, Yuefei Ren, Ye Tian, Wenxuan Cai, Yifeng Bao, Qi Liu, Peng Ding, Yi Li
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionThe presence of soluble human programmed cell death-ligand 1 (shPD-L1) in the blood of patients with cancer has been reported to be negatively correlated with disease prognosis. However, little information exists about the mechanisms unde
Externí odkaz:
https://doaj.org/article/1a86a3faeb824355a72a50990af9c493
Publikováno v:
PLoS ONE, Vol 17, Iss 7, p e0266013 (2022)
The transportation industry has entered a new stage from quantity expanding to structure optimization, quality and efficiency improvement, and from respective governance to integrative development. This indicates that the traditional corridor mode al
Externí odkaz:
https://doaj.org/article/61df117d82294a7fb21a771275205bee
Autor:
Ye Tian, Qi Liu, Yanyan Li, Wei Zhang, Yi Li, Wenxuan Cai, Yaju Liu, Yuefei Ren, Zhaoduan Liang, Peipei Zhou, Yajing Zhang, Yifeng Bao
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Background In patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), virus-specific cytotoxic T lymphocytes (CTLs) fail to eliminate HCC cells expressing HBV antigens. As the expression of viral antigen in HBV-associated HCC ma
Externí odkaz:
https://doaj.org/article/336cfd26b9ce46988230fde6f80ab0ae
Autor:
Haoru Dong, Donglei Shi, Yifeng Bao, Xingyu Chen, Longnian Zhou, Haiyue Lin, Yuanqing Ding, Jinping Liu, Jian Yu, Rong Xie
Publikováno v:
Journal of Neurorestoratology. 11:100056
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::784646d9de12f00c7b0ce408ccc2286c
https://doi.org/10.1016/j.jnrt.2023.100056
https://doi.org/10.1016/j.jnrt.2023.100056
Autor:
Zhaoduan Liang, Wenfang Chen, Yunzhuo Guo, Yuefei Ren, Ye Tian, Wenxuan Cai, Yifeng Bao, Qi Liu, Peng Ding, Yi Li
Publikováno v:
Frontiers in Immunology; 2023, p1-12, 12p
Autor:
Yifeng Bao, Siqi Peng
Publikováno v:
Annals of Blood. 7:33-33
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::84fe9f99289a8dc083cf87c6b3d9278b
https://doi.org/10.21037/aob-21-3
https://doi.org/10.21037/aob-21-3
Autor:
Johnny S. H. Kwan, Qisheng Tang, Yifeng Bao, Ying Mao, Hong Chen, Zhifeng Shi, Rui Ryan Yang, Abudumijiti Aibaidula, Ho Keung Ng, Kay Ka-Wai Li
Publikováno v:
Brain Pathol
Giant cell glioblastoma (gcGBM) is a rare histological variant of GBM, accounting for about 1% of all GBM. The prognosis is poor generally though gcGBM does slightly better than the other IDH‐wild‐type GBM. Because of the rarity of the cases, the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6f9baa37163eddbf9b855924fe08d3f
https://doi.org/10.1111/bpa.12720
https://doi.org/10.1111/bpa.12720
Publikováno v:
Frontiers of Medicine. 13:69-82
Cytokine-activated T cells (CATs) can be easily expanded and are widely applied to cancer immunotherapy. However, the good efficacy of CATs is rarely reported in clinical applications because CATs have no or very low antigen specificity. The low-effi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::061c62a665a68e79c527e35fe24e0394
https://doi.org/10.1007/s11684-018-0677-1
https://doi.org/10.1007/s11684-018-0677-1
Autor:
Yanyan Li, Yaju Liu, Peipei Zhou, Li Yi, Zhaoduan Liang, Wenxuan Cai, Yifeng Bao, Ye Tian, Yuefei Ren, Yajing Zhang, Wei Zhang, Qi Liu
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundIn patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), virus-specific cytotoxic T lymphocytes (CTLs) fail to eliminate HCC cells expressing HBV antigens. As the expression of viral antigen in HBV-associated HCC may
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::236372fe823b071dbec12012b2b4934f
https://jitc.bmj.com/content/8/2/e001748.full
https://jitc.bmj.com/content/8/2/e001748.full
Autor:
Anan Chen, Shiyue Li, Yanyan Li, Xiaoping Liu, Qiang Liu, Cassian Yee, Huanling Zhang, Yi Li, Zhaoduan Liang, Chengzhi Zhou, Yifeng Bao, Mengyong Yan
Publikováno v:
Immunology. 155:238-250
Recently, bi-functional molecules that can redirect immune effectors to tumour cells have emerged as potentially robust mediators of tumour regression in clinical trials. Two modalities in particular, bi-specific antibodies for T-cell redirection and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe988254485dd3258e4386185aaccf71
https://doi.org/10.1111/imm.12954
https://doi.org/10.1111/imm.12954